跳至主要内容
临床试验/NCT05317962
NCT05317962已完成不适用

Cardiac Manifestations of COVID-19 in Patients Admitted to Hospital

London North West Healthcare NHS Trust1 个研究点 分布在 1 个国家目标入组 251 人开始时间: 2020年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
251
试验地点
1
主要终点
Prevalence of cardiac abnormalities and relationship to admission to ICU

研究概览

简要总结

Investigation of the cardiac manifestations of COVID-19 in patients admitted to hospital

详细描述

The COVID-19 disease (caused by SARS-CoV-2) predominantly affects the lungs causing a pneumonia which can become severe and lead to death via a severe inflammatory response in the lungs for which patients require admission to intensive care units (ICU) and artificial ventilation of their lungs. However, early reports from China have documented an element of injury to the heart present in up to 20% of patients. They have also documented patients who have died on ICU from heart injury rather than lung injury in COVID-19 positive patients. There are increasing numbers of reports of patients with COVID-19 having significant inflammation of the heart. What is not known is the prevalence of significant inflammation of the heart secondary to the SARS-CoV-2 and also what the significance of the injury to the heart shown in 20% of patients through blood tests really represents. That is to say is the injury significant to the outcome of the patient?

In order to investigate this, it is proposed to conduct a heart scan in COVID-19 positive patients in hospital to determine what form of heart injury is caused by the disease as well as determining it's prevalence and whether a heart scan helps in risk stratifying the patient in terms of outcome. If it is found that there is a significant amount of heart injury done by the SARS-CoV-2 and it can be determined this at an early stage with a heart scan it may be possible to start a more aggressive strategy for the patient's management in hospital to reduce the chance of death. Alternatively, if it is found that the incidence of heart injury is low and a heart scan makes no difference to the management of the patient, medical teams can be advised of this.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years old
  • Positive swab or serology for COVID-19
  • Referred for echocardiographic evaluation for clinical reasons
  • Willing and able to give assent

排除标准

  • Known hypersensitivity to perflutren or known excipients in LUMINITY

结局指标

主要结局

Prevalence of cardiac abnormalities and relationship to admission to ICU

时间窗: 6 weeks from start of admission

次要结局

  • Prevalence of cardiac abnormalities and relationship to need for mechanical ventilation(6 weeks from start of admission)
  • Prevalence of cardiac abnormalities and relationship to death or discharge(6 weeks from start of admission)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

COVID-19 Echo Study | 临床试验